chemotherapy/hemorrhage

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to compositions comprising membrane-derived microparticles that promote platelet adhesion, aggregation, blood clot formation and to a method for treating bleeding disorders, particularly blood coagulation disorders, platelet

BACKGROUND OF THE INVENTION Hematological disorders are blood associated disorders. Blood is a highly specialized tissue which carries oxygen and nutrients to all parts of the body and waste products back to the lungs, kidneys and liver for disposal. Thus, blood maintains communication between

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets. DETAILED DESCRIPTION OF THE INVENTION The compounds of the Formula I are old compounds

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets. DETAILED DESCRIPTION OF THE INVENTION The compounds of the Formula I are old compounds

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula I to the plasma surrounding the platelets. DETAILED DESCRIPTION OF THE INVENTION The compounds of the Formula I are old compounds

TECHNICAL FIELD The present invention relates to a novel physiologically active substance (thrombocytopoiesis stimulating factor) having activity in acting on cells in the megakaryocyte system, in promoting their differentiation and maturation, and in promoting the formation of platelets, as well as

FIELD OF THE INVENTION The invention is directed to the field of stem cell survival and expansion. Specifically, the invention is directed at the stem cell survival and expansion effects of peptides derived from acetylcholinesterase. In addition, the invention relates to a system for screening of

FIELD OF THE INVENTION The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment, the

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets. DETAILED DESCRIPTION The compounds of the Formula 1 are old compounds known in the art.

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets. DETAILED DESCRIPTION OF THE INVENTION The compounds of the Formula 1 are old compounds

BRIEF DESCRIPTION OF THE INVENTION This invention relates to the prevention of platelet aggregation or thrombus formation by the addition of a compound of the Formula 1 to the plasma surrounding the platelets. DETAILED DESCRIPTION OF THE INVENTION The compounds of the Formula 1 are old compounds

The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor

The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor

FIELD OF THE INVENTION The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly

FIELD OF THE INVENTION The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly